Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Nulixir Inc. maintains a portfolio in the Biotechnology & Pharmaceuticals technology area with 6 pending office actions currently active. These actions are distributed across 6 distinct examiners. This distribution suggests that the company is engaging with a variety of perspectives within the patent office rather than having its workload concentrated under a single person. The prosecution activity spans 5 distinct art units, which indicates that the company's 6 pending office actions are being evaluated across multiple technical divisions.
The busiest examiner identified is WORSHAM, JESSICA N, who is currently handling 1 pending office action. Given that the total number of pending office actions is 6, this examiner's individual workload represents a portion of the overall portfolio activity. Practitioners should note that the diversity of 6 distinct examiners across 5 distinct art units requires a strategy that accounts for multiple examination styles and potentially different interpretations of biotechnology standards. This lack of concentration across the 6 pending office actions means that the company must maintain a broad approach to its prosecution efforts to satisfy the requirements of 5 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WORSHAM, JESSICA N | 1 | 56.3% | +56.3% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
| MEYERS, ELIZABETH ANNE | 1 | 23.5% | +92.9% |
| KIM, DANIELLE A | 1 | 37.1% | +56.3% |
| ATKINSON, JOSHUA ALEXANDER | 1 | 52.4% | +26.7% |
| TCHERKASSKAYA, OLGA V | 1 | 55.4% | +46.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18447240 | ENCAPSULATED VITAMIN D | WORSHAM, JESSICA N | — |
| 17945011 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | MEYERS, ELIZABETH ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18447240 | ENCAPSULATED VITAMIN D | WORSHAM, JESSICA N | — |
| 18168394 | ENCAPSULATED PRECURSORS OF NICOTINAMIDE ADENINE DINUCLEOTIDE AND METHODS OF MAKING THE SAME | CHO, DAVID H | — |
| 17945011 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | MEYERS, ELIZABETH ANNE | — |
| 17945037 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | KIM, DANIELLE A | — |
| 17945038 | ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MAKING THE SAME | ATKINSON, JOSHUA ALEXANDER | — |
| 17470994 | METHODS AND SYSTEMS FOR FORMING MULTI-LAYERED PARTICLES | TCHERKASSKAYA, OLGA V | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1693 | 1 |
| 1617 | 1 |
| 1613 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18447240 | ENCAPSULATED VITAMIN D | WORSHAM, JESSICA N | 1615 | §102§103§112 | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18168394 | ENCAPSULATED PRECURSORS OF NICOTINAMIDE ADENINE DINUCLEOTIDE AND METHODS OF MAKING THE SAME | CHO, DAVID H | 1693 | §103DP | Final Rejection | — | Pending | Feb 13, 2023 |
| 17945011 | ORAL COMPOSITIONS WITH PLANT MATTER EXTRACTS AND METHODS OF MAKING THE SAME | MEYERS, ELIZABETH ANNE | 1617 | §103§112 | Non-Final OA | — | Pending | Sep 14, 2022 |
| 17945037 | STABLE NON-AQUEOUS COMPOSITIONS OF FUNCTIONAL INGREDIENTS AND METHODS OF MAKING THE SAME | KIM, DANIELLE A | 1613 | §103 | Final Rejection | — | Pending | Sep 14, 2022 |
| 17945038 | ORAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY AND METHODS OF MAKING THE SAME | ATKINSON, JOSHUA ALEXANDER | 1612 | §112DPOther | Non-Final OA | — | Pending | Sep 14, 2022 |
| 17470994 | METHODS AND SYSTEMS FOR FORMING MULTI-LAYERED PARTICLES | TCHERKASSKAYA, OLGA V | 1615 | §112 | Final Rejection | — | Pending | Sep 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial